Acepodia (6976) Fundamentals 2026 — Revenue Analysis | SniperIQ
Acepodia (6976) is a KY-listed Healthcare company in Biotechnology with a market capitalization of NT$7.4B, trading at NT
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Acepodia's market cap?
Acepodia (6976) has a market capitalization of approximately NT$7.4B, trading at NT
What is Acepodia's P/E ratio?
Acepodia's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Acepodia?
Acepodia runs a net profit margin of -407784.3%, a gross margin of -30894.6%, and an operating margin of -523891.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Acepodia generate?
Acepodia reported revenue of NT
Does Acepodia pay a dividend?
Acepodia does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Acepodia financially healthy?
Acepodia carries a debt-to-equity ratio of 0.05x and a current ratio of 20.29x, with a market beta of 0.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Acepodia a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Acepodia (6976) the key facts are: market cap NT$7.4B, revenue NT
Track Acepodia's full fundamentals live
Get Acepodia's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.